EMA Recommends Extension of Indications for Darolutamide
New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with docetaxel and androgen deprivation therapy
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer
Findings from the GALAXY, an observational arm of the ongoing CIRCULATE-Japan study
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
Evidence for efficacy is based on the results from the SEQUOIA and ALPINE studies
Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable Colon Cancer, Producing Marked Histopathologic Downstaging and Disease Control
Findings from the FOxTROT study
FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer
Evidence for efficacy is based on the results from the MOUNTAINEER study
Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic Cholangiocarcinoma Harbouring FGFR2 Fusions or Other Rearrangements
Findings from the FOENIX-CCA2 study
When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic and Predictive Value of RNA Sequencing–Based Immune Signatures is Superior
Findings from a correlative analysis of the CALGB 40601 and PAMELA studies in patients with early HER2-positive breast cancer
A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations in An Observational Pancancer Setting
Findings highlight a complex relationship between immune-related adverse events and clinical outcome
FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin Unresponsive Non-Muscle Invasive Bladder Cancer
Evidence for efficacy is based on the results from the Study CS-003
Higher Event-Free Survival with Addition of Crizotinib to a Standard Chemotherapy Backbone for Children with ALK-positive Anaplastic Large-Cell Lymphoma
An unexpected increase in the number of thromboembolic events observed in crizotinib arm of the ANHL12P1 study
Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals After Up To 5 Years of Follow-Up in Patients with Metastatic Urothelium Cancer
Findings from the KEYNOTE-045 study in patients with platinum-resistant metastatic urothelial cancer and from the KEYNOTE-052 as first-line treatment for cisplatin-ineligible patients
Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity in Patients with Localised dMMR Solid Tumours
The results of a phase II study of neoadjuvant pembrolizumab for patients with localised mismatch repair deficient/microsatellite instability-high solid tumours